Targeted therapies in gastroesophageal cancer

详细信息    查看全文

• 作者：Stefan Kasper^a ; Martin Schuler^a ; ^b ; ^{martin.schuler@uk-essen.de" class="auth_mail}
• 关键词：ACCORD ; Action Clinique COordonn&eacute ; es en canc&eacute ; rologie Digestive ; AVAGAST ; Avastin in Gastric Cancer trial ; CLEOPATRA ; Clinical Evaluation of Pertuzumab and Trastuzumab ; DCR ; Disease control rate ; ERBB ; Erythroblastic Leukemia Viral Oncogene ; EXPAND ; Erbitux in combination with Xeloda and cisPlatin in AdvaNceD esophagogastric cancer ; FAST ; First-Line Treatment of Patients with CLDN18.2-Positive adenocarcinomas of the stomach ; the esophagus or the gastroesophageal junction ; FOLFOX ; Fol
• 刊名：European Journal of Cancer
• 出版年：May, 2014
• 年：2014
• 卷：50
• 期：7
• 页码：1247-1258
• 全文大小：993 K

文摘

Gastroesophageal cancers comprising gastric cancer (GC), and cancers of the distal oesophagus and gastroesophageal junction (GEJ) are a global health threat. In Western populations the incidence of GC is declining which has been attributed to effective strategies of eradicating Helicobacter pylori infection. To the contrary, GEJ cancers are on the rise, with obesity and reflux disease being viewed as major risk factors. During the past decade perioperative chemotherapy, pre- or postoperative radio-chemotherapy, and, in Asian populations, adjuvant chemotherapy have been shown to improve the outcome of patients with advanced GC and GEJ cancers suited for surgery. Less progress has been made in the treatment of metastatic disease. The introduction of trastuzumab in combination with platinum/fluoropyrimidine-based chemotherapy for patients with HER2-positive disease has marked a turning point. Recently, several novel agents targeting growth factor receptors, angiogenic pathways, adhesion molecules and mediators of intracellular signal transduction have been clinically explored. Here we summarise the current status and future developments of molecularly targeted therapies in GC and GEJ cancer.